Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus

References

• Cahn A, Cernea S, Raz I. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Dec;21(4):409–419.
   PubMed Web of Science ®Google Scholar
• Cernea S, Cahn A, Raz I. Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opin Drug Saf. 2016 May;15(5):697–707.
   PubMed Web of Science ®Google Scholar
• Ahren B. DPP-4 inhibition and the path to clinical proof. Front Endocrinol (Lausanne). 2019;10:376.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs. 2013 Jun;18(2):245–258.
   PubMed Web of Science ®Google Scholar
• Gong Q, Rajagopalan S, Zhong J. Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: incretin-dependent and -independent function. Int J Cardiol. 2015 Oct 15;197:170–179.
   PubMed Web of Science ®Google Scholar
• Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis. 2013 Feb;226(2):305–314.
   PubMed Web of Science ®Google Scholar
• Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013 Jun 4;17(6):819–837.
   PubMed Web of Science ®Google Scholar
• Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009 May;5(5):262–269.
   PubMed Web of Science ®Google Scholar
• Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986 Jan;29(1):46–52. .
   PubMed Web of Science ®Google Scholar
• Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011 Jan;124(1 Suppl):S3–18.
   PubMed Web of Science ®Google Scholar
• Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005 Jul 28;48(15):5025–5037.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Weber J. Saxagliptin. Drugs. 2009 Oct 22;69(15):2103–2114.
   PubMed Web of Science ®Google Scholar
• Anderson R, Hayes J, Stephens JW. Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes. Expert Opin Drug Metab Toxicol. 2016;12(4):467–473.
   PubMed Web of Science ®Google Scholar
• Chen XW, He ZX, Zhou ZW, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Oct;42(10):999–1024.
   PubMed Web of Science ®Google Scholar
• Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501–514.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015 Apr;14(4):505–524.
   PubMed Web of Science ®Google Scholar
• Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet. 2011 Apr;50(4):253–265.
   PubMed Web of Science ®Google Scholar
• Fura A, Khanna A, Vyas V, et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos. 2009 Jun;37(6):1164–1171.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015 Jan;54(1):1–21.
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011 Jul 30;71(11):1441–1467.
   PubMed Web of Science ®Google Scholar
• Tong L, Adler S. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgrad Med. 2018 May;130(4):381–393.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009 Oct;25(10):2401–2411.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009 Sep;32(9):1649–1655.
   PubMed Web of Science ®Google Scholar
• Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009 Sep;63(9):1395–1406.
   PubMed Web of Science ®Google Scholar
• Hollander PL, Li J, Frederich R, et al. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2011 Apr;8(2):125–135.
   PubMed Web of Science ®Google Scholar
• Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012 Apr;28(4):513–523.
   PubMed Web of Science ®Google Scholar
• Sjostrand M, Wei C, Cook W, et al. Assessment of saxagliptin efficacy: meta-analysis of 14 Phase 2 and 3 clinical trials. Diabetes Ther. 2017 Jun;8(3):587–599.
   PubMed Web of Science ®Google Scholar
• Men P, Li XT, Tang HL, et al. Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS One. 2018;13(5):e0197321.
   PubMed Web of Science ®Google Scholar
• Messori A, Fadda V, Maratea D, et al. Testing the therapeutic equivalence of alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin as monotherapy or in combination with metformin in patients with type 2 diabetes. Diabetes Ther. 2014 Jun;5(1):341–344.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3;369(14):1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 Jul 16;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with Type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019 Jan 1;321(1):69–79.
   PubMed Web of Science ®Google Scholar
• Fayyaz B, Rehman HJ, Minn H. Interpretation of hemoglobin A1C in primary care setting. J Community Hosp Intern Med Perspect. 2019;9(1):18–21.
   PubMed Web of Science ®Google Scholar
• Hirshberg B, Parker A, Edelberg H, et al. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2014 Oct;30(7):556–569.
   PubMed Web of Science ®Google Scholar
• Davidson JA. Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies. J Manag Care Pharm. 2014 Feb;20(2):120–129.
   PubMed Web of Science ®Google Scholar
• Liu J, Li L, Deng K, et al. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ. 2017 Jun 8;357:j2499.
   PubMed Web of Science ®Google Scholar
• Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013 Jul 29;347:f4533.
   PubMed Web of Science ®Google Scholar
• Salvo F, Moore N, Arnaud M, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ. 2016 May 3;353:i2231.
   PubMed Web of Science ®Google Scholar
• Kim J, Samson SL. Cardiovascular effects of incretin therapy in diabetes care. Metab Syndr Relat Disord. 2014 Aug;12(6):303–310.
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012 Apr;33(2):187–215.
   PubMed Web of Science ®Google Scholar
• Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol. 2015 Sep 29;14:129.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Duran-Garcia S, Hanefeld M, et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes Metab. 2015 Jul;17(7):630–638.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SRK, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215–2222.
   PubMed Web of Science ®Google Scholar
• Pala L, Rotella CM. The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence. J Diabetes Res. 2013;2013:590456.
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014 May 23;114(11):1788–1803.
   PubMed Web of Science ®Google Scholar
• Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010 May;122(3):16–27.
   PubMed Web of Science ®Google Scholar
• Iqbal N, Parker A, Frederich R, et al. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol. 2014 Feb 4;13:33.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457–2471.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23;385(9982):2067–2076.
   PubMed Web of Science ®Google Scholar
• Raschi E, Poluzzi E, Koci A, et al. Dipeptidyl peptidase-4 inhibitors and heart failure: analysis of spontaneous reports submitted to the FDA adverse event reporting system. Nutr Metab Cardiovasc Dis. 2016 May;26(5):380–386.
   PubMed Web of Science ®Google Scholar
• Baksh SN, McAdams-DeMarco M, Segal JB, et al. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients. Pharmacoepidemiol Drug Saf. 2018 Jun;27(6):660–667.
   PubMed Web of Science ®Google Scholar
• Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016 Feb 17;352:i610.
   PubMed Web of Science ®Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med. 2014 Feb 27;370(9):794–797.
   PubMed Web of Science ®Google Scholar
• Suarez EA, Koro CE, Christian JB, et al. Incretin-mimetic therapies and pancreatic disease: a review of observational data. Curr Med Res Opin. 2014 Dec;30(12):2471–2481.
   PubMed Web of Science ®Google Scholar
• Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with Type 2 diabetes. Diabetes Care. 2017 Feb;40(2):284–286.
   PubMed Web of Science ®Google Scholar
• Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014 Apr 15;348:g2366.
   PubMed Web of Science ®Google Scholar
• Giorda CB, Sacerdote C, Nada E, et al. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2015 Mar;48(2):461–471.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014 Jan;16(1):48–56.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Filion KB, Platt RW, et al. Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med. 2016 Oct 1;176(10):1464–1473.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018 Apr;17(4):387–405.
   PubMed Web of Science ®Google Scholar
• Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. Diabetes Care. 2014 Sep;37(9):2435–2441.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Filion KB, Platt RW, et al. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ. 2016 Feb 17;352:i581.
   PubMed Web of Science ®Google Scholar
• Lee M, Sun J, Han M, et al. Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors. Diabetes Care. 2019 Nov;42(11):2057–2064.
   PubMed Web of Science ®Google Scholar
• Abrahami D, Douros A, Yin H, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ. 2018 Dec 5;363:k4880.
   PubMedGoogle Scholar
• Rehman MB, Tudrej BV, Soustre J, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2017 Feb;43(1):48–58.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care. 2017 Jan;40(1):69–76.
   PubMed Web of Science ®Google Scholar
• Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015 Apr;38(4):696–705.
   PubMed Web of Science ®Google Scholar
• Barbehenn E, Almashat S, Carome M, et al. Hepatotoxicity of alogliptin. Clin Pharmacokinet. 2014 Nov;53(11):1055–1056.
   PubMed Web of Science ®Google Scholar
• Tang W, Xu Q, Hong T, et al. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. Diabetes Metab Res Rev. 2016 Feb;32(2):200–216.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhao C, Liang J, et al. Effect of dipeptidyl peptidase-4 inhibitors on bone metabolism and the possible underlying mechanisms. Front Pharmacol. 2017;8:487.
   PubMed Web of Science ®Google Scholar
• Mamza J, Marlin C, Wang C, et al. DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;116:288–298.
   PubMed Web of Science ®Google Scholar
• Dombrowski S, Kostev K, Jacob L. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data. Osteoporos Int. 2017 Aug;28(8):2421–2428.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Wei C, Davidson J, et al. Incidence of fractures in patients with Type 2 diabetes in the SAVOR-TIMI 53 trial. Diabetes Care. 2015 Nov;38(11):2142–2150.
   PubMed Web of Science ®Google Scholar
• Mendonca FM, Martin-Gutierrez FJ, Rios-Martin JJ, et al. Three cases of bullous pemphigoid associated with dipeptidyl Peptidase-4 inhibitors - One due to linagliptin. Dermatology. 2016;232(2):249–253.
   PubMed Web of Science ®Google Scholar
• Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis. Australas J Dermatol. 2020 Feb;61(1):e15–e21.
   PubMed Web of Science ®Google Scholar
• Bene J, Moulis G, Bennani I, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol. 2016 Aug;175(2):296–301.
   PubMed Web of Science ®Google Scholar
• Arai M, Shirakawa J, Konishi H, et al. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database. Diabetes Care. 2018 Sep;41(9):e130–e132.
   PubMed Web of Science ®Google Scholar
• Carnovale C, Mazhar F, Arzenton E, et al. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase(R). Expert Opin Drug Saf. 2019 Nov;18(11):1099–1108.
   PubMed Web of Science ®Google Scholar
• Mascolo A, Rafaniello C, Sportiello L, et al. Dipeptidyl Peptidase (DPP)-4 inhibitor-induced Arthritis/Arthralgia: A review of clinical cases. Drug Saf. 2016 May;39(5):401–407.
   PubMed Web of Science ®Google Scholar
• Men P, He N, Song C, et al. Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis. Diabetes Metab. 2017 Dec;43(6):493–500.
   PubMed Web of Science ®Google Scholar
• Antonazzo IC, Poluzzi E, Forcesi E, et al. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. Acta Diabetol. 2020 Jan;57(1):71–80.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011 Aug;32(4):515–531.
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013 Oct;1(2):140–151.
   PubMed Web of Science ®Google Scholar
• Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011 May 3;154(9):602–613.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care. 2015 Mar;38(3):373–375.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015 Mar;38(3):376–383.
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Ekholm E, Johnsson E, et al. Dapagliflozin plus saxagliptin add-on therapy compared with insulin in patients with Type 2 diabetes poorly controlled by metformin with or without sulfonylurea therapy: a randomized clinical trial. Diabetes Care. 2019 Aug;42(8):1464-1472.
   Web of Science ®Google Scholar
• Garnock-Jones KP. Saxagliptin/Dapagliflozin: a review in Type 2 diabetes mellitus. Drugs. 2017 Mar;77(3):319–330.
   PubMed Web of Science ®Google Scholar
• Coppenrath VA, Hydery T. Dapagliflozin/ saxagliptin fixed-dose tablets: a new sodium-glucose cotransporter 2 and dipeptidyl peptidase 4 combination for the treatment of Type 2 diabetes. Ann Pharmacother. 2018 Jan;52(1):78–85.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Bonora BM, Mayur S, et al. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018 Mar;20(3):740–744.
   PubMed Web of Science ®Google Scholar
• Xia C, Goud A, D’Souza J, et al. DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. Heart Fail Rev. 2017 May;22(3):299–304.
   PubMed Web of Science ®Google Scholar
• Koyani CN, Kolesnik E, Wolkart G, et al. Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure. Biochem Pharmacol. 2017 Dec 1;145:64–80.
   PubMed Web of Science ®Google Scholar
• Koyani CN, Trummer C, Shrestha N, et al. Saxagliptin but not sitagliptin inhibits CaMKII and PKC via DPP9 inhibition in cardiomyocytes. Front Physiol. 2018;9:1622.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Singh A, Sharma A, et al. Contemporary trends in prescription of dipeptidyl Peptidase-4 inhibitors in the context of US food and drug administration warnings of heart failure risk. Am J Cardiol. 2020 May 15;125(10):1577–1581.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2016 Nov 10;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 Oct 27;392(10157):1519–1529.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2017 Sep 28;377(13):1228–1239.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015 Dec 3;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130.
   Google Scholar
• Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with Type 2 diabetes: a randomized clinical trial. JAMA. 2017 Oct 17;318(15):1460–1470.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial comparing the efficacy and safety of oral semaglutide monotherapy with placebo in patients with Type 2 diabetes. Diabetes Care. 2019 Sep;42(9):1724-1732.
   Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with Type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019 Apr 16;321(15):1466-1480.
   Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2019 Aug 29;381(9):841-851..
   Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017 Aug 17;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2019 Jan 24;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Introduction: standards of medical care in diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S1–S2.
   PubMed Web of Science ®Google Scholar
• Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019 Jun 4;170(11):764–769.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Sarangdhar M, De Ponti F, et al. Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2019;7(1):e000725.
   PubMed Web of Science ®Google Scholar
• Cattadori G, Pantanetti P, Ambrosio G. Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes. Diabetes Res Clin Pract. 2019 Nov;157:107835.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014 Feb;124(2):499–508.
   PubMed Web of Science ®Google Scholar
• Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014 Feb;124(2):509–514.
   PubMed Web of Science ®Google Scholar